Skip to main content

Table 1

From: Efficacy and safety profile of a novel technique, ThuLEP (Thulium laser enucleation of the prostate) for the treatment of benign prostate hypertrophy. Our experience on 148 patients

 

Preoperative Mean ± SD (Range)

Postoperative Mean ± SD (Range)

No. of patients

148

122

Age (years)

68, 2 ± 5,03 (47 – 85)

 

PSA (ng/ml)

9,53 ± 8,32 (1,5- 40,2)

0,93 ± 0,67 (0,12 – 3,56)

Prostate Volume (ml)

108,08 ± 24,23 (75 – 210)

13,76 ± 9,47 (4 – 43)

IPSS

21,10 ± 7,12 (8 – 35)

3,90 ± 2,42 (0 – 14)

QoL

4,38 ± 1, 32 (1 – 6)

0,94 ± 0,67 (0 – 4)

Qmax (ml/sec)

8, 23 ± 3,65 (1,3 – 15)

28,67 ± 10,67 (15 – 56)

PVR (ml)

146,12 ± 132,32 (40 – 600)

12,89 ± 20,87 (1 – 128)

IIEF-5 score

19,3 ± 8,23 (6- 30)

20,3 ± 8,16 (6 – 30)

  

p< 0,05